Study the Result of Ayurvedic SUVED & Reimmugen (Colostrum) Treatment on Vascular Disease, CAD, CVA, DVT. (SHARP)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02920125|
Recruitment Status : Completed
First Posted : September 30, 2016
Last Update Posted : September 26, 2017
|Condition or disease||Intervention/treatment||Phase|
|Coronary Artery Disease Cerebro Vascular Disease Ischemic Heart Disease Deep Vein Thrombosis Peripheral Arterial Diseases Vascular Disease||Drug: SUVED Combination Product: REIMMUGEN Other: Grain flour placebo||Phase 3|
Aim: A non-invasive, effective, compatible, Integrative treatment option to address the growing burden of Vascular disease; Importance: Ayurvedic SUVED (cardio tonic, continuous clotlysis, endothelial repair, powerful rejuvenator, antioxidant) and Reimmugen (Cow Colostrum - IgG, GF) provides sustained Functional, symptomatic relief with clinical reports of regression of disease. No adverse interactions reported.
Application: Addition of SUVED & REIMMUGEN helps in:
- Acute MI, Thrombotic stroke, DVT, hastens symptomatic recovery, reduces hospitalization time, mortality, helps dissolve clots / soft thrombus; reversal of atherosclerotic plaques; improves functional life
- Improvements in Cardiac Function : LVEF; Global perfusion
- Rejuvenation of endothelium, vascular function.
- Improved physical strength: digestion; GI function; immunity; accelerated internal healing
- Secondary prevention to avoid incidences in post event treatment.
Health condition/problem studied Vascular disease, esp CVA, IHD, CAD, DVT, PAD Volunteers taken from OPD and IPD of SKNMC & GH with prior consent for participation.
Intervention is Medicament based given in addition to conventional ongoing therapy under the guidance of SKNMC doctors.
Study type Clinical trial: Double Blind placebo controlled trial. Interventional Trial: regular treatment. Evaluation of additional Integrative esp Ayurvedic medicaments on clinical and functional outcome.
Intervention and comparator agent
- Ayurvedic ghana formulation named SUVED.
- Whole Cow Colostrum called Reimmugen These will be given for a period of three months in addition to ongoing medication to study the additional benefit to patient in their functional and clinical investigations.
The control intervention/s is/are the interventions against which the study intervention is evaluated as double blind placebo.
Suved 1 BD for 3 months Reimmugen 1 TDS for 3 months In acute cases Suved 1 TDS Reimmugen 2 TDS for 3 months. Inclusion/ Exclusion criteria Inclusion criteria
Adult males or females with a diagnosis of Vascular disease leading to IHD, CAD, CVA, DVT, PAD at any stage.
Pregnant and lactating women, Patients below age of 18 Acute IPD operative condition Patients undergoing interventional procedures / surgical treatments other than for Vascular disease; until they are discharged from intensive care; Haemorrhagic cerebro vascular stroke.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||96 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||Double Blind, Placebo controlled, two arm, on patients of vascular disease / atherosclerosis. Intervention is given in addition to ongoing conventional therapy.|
|Masking:||Triple (Participant, Investigator, Outcomes Assessor)|
For subjects/patients -Control and Trial medication are packaged in same looking blister / alu alu strips.
For Investigator and Outcome Assessor: no information on patient allocation (trial or Control group)
|Official Title:||A Study to Evaluate the Results of Integrative Treatment (by Including Ayurvedic Capsules Suved & Reimmugen) for Vascular Disease: Namely: Cerebro Vascular Accident - Embolic and Atherosclerotic, CVA, CAD, IHD,DVT,|
|Actual Study Start Date :||January 2016|
|Actual Primary Completion Date :||August 2017|
|Actual Study Completion Date :||September 2017|
Active Comparator: Trial: Ayurvedic SUVED, REIMMUGEN
Ayurvedic SUVED formulation comprises of 'Ghana' extract form; Dosage :3 months, 1 BD. Content: (500mg per capsule)Terminalia Arjuna: Withania somnifera; Terminalia chebula; Cyperus rotundus; Apium graveolens; Vitis vinifera; Piper longum; Fagonia Arabica; Emblica officinalis; Terminalia belerica; Nymphaea stellata; Punica granatum; Bacopa Monnieri; and stabilizing herbs.
Reimmugen Cow-colostrum is a total natural product, used as nutritional supplement Dosage: 3months, 1 TDS Contents: IgA, IgE, IgM, IgG, IgD, PRPs, Lactoferrin, Transferrin, Interferons, Cytokines, Growth Factors (bFGF, vFGF, IGF I & II & Angiogenesis growth Factor, Endothelial growth Factor, Nerve growth factor, PDGF), natural Vitamins and Minerals.
Ayurvedic formulation in ghana (concentrated) in capsules; 500 mg each
Other Name: Ayurvedic Suved
Combination Product: REIMMUGEN
Whole Cow colostrum in powder put in capsules; 300mg each
Other Name: Reimmugen Cow Colostrum
Placebo Comparator: Control: grain flour
Dummy medication in same packing to mask content given in same dose as active medication. Jowari and ragi flour used in capsules
Other: Grain flour placebo
Grain flour in capsules. Jowari flour in dummy Reimmugen and Ragi flour in dummy Suved placebos
- changes in IMT as a indicator of atherosclerosis reversal [ Time Frame: 3 months active treatment ]Restoration of carotid IMT to non pathological state, supported with positive changes in functionality, relief from associated symptoms during treatment period of 3 months.
- Assessing the development/risk of ischaemic events in other circulations [ Time Frame: 3 months ]
Secondary outcomes assessing the development/risk of ischaemic events in other circulations. Eg; in a stroke patient, evaluation of coronaries.
Evaluations done within the study period of 3 months for each patient.
To study the occurance of new events in other territory.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02920125
|Smt Kashibai Navle Medical College and General Hospital|
|Pune, Maharashtra, India, 411041|
|Principal Investigator:||Dr Shreepad M Bhat, MD||Smt Kashibai Navle Medical College & Gen Hospital|